DexTech Medical Overview

  • Founded
  • 2004
  • Status
  • Public
  • Employees
  • 1
  • Stock Symbol
  • DEX
Stock Symbol
  • Share Price
  • $5.31
  • (As of Tuesday Closing)

DexTech Medical General Information


DexTech Medical AB develops candidate medications with applications within urological oncology, primarily for prostate cancer. Its medication candidates include GuaDex, OsteoDex, and SomaDex, among others. The company conducts operations in medical research with the development of new drug candidates mainly in urological oncology, but also other cancer diseases and for non-malignant diseases.

Contact Information

Ownership Status
Publicly Held
Financing Status
Primary Industry
Drug Discovery
Stock Exchange
Primary Office
  • Box 389
  • 751 06 Uppsala
  • Sweden
+46 070-710 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

DexTech Medical Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.31 $5.42 $3.62 - $8.19 $79.2M 14.9M 3.05K -$0.05

DexTech Medical Financials Summary

In Thousands,
TTM 30-Sep-2020 FY 2020 30-Jun-2020 FY 2019 30-Jun-2019 FY 2018 30-Jun-2018
EV 69,864 77,681 124,352 77,102
Revenue 0 0 0 0
EBITDA (172) (217) (146) (130)
Net Income (766) (800) (913) (1,060)
Total Assets 1,318 1,430 2,418 2,298
Total Debt 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

DexTech Medical Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial